CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

Phase 2

Completed

Conditions: Myelodysplastic Syndromes
Leukemia, Myeloid, Acute

Interventions: Drug: Azacitidine
Biological: Durvalumab

First Posted Date: 2016-05-18

Last Posted Date: 2023-02-28

Lead Sponsor: Celgene

Target Recruit Count: 213

Registration Number: NCT02775903

Locations: 🇧🇪
Grand Hopital de Charleroi, Charleroi, Belgium
🇦🇹
Salzburger Landkliniken St. Johanns-Spital, Salzburg, Austria
🇦🇹
AKH Wien, Wein, Austria

and more 100 locations

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: CC-220
Drug: Dexamethasone
Drug: Daratumumab
Drug: Carfilzomib
Drug: Bortezomib

First Posted Date: 2016-05-16

Last Posted Date: 2024-06-25

Lead Sponsor: Celgene

Target Recruit Count: 466

Registration Number: NCT02773030

Locations: 🇺🇸
Local Institution - 101, Atlanta, Georgia, United States
🇺🇸
Local Institution - 108, Hackensack, New Jersey, United States
🇺🇸
Local Institution - 115, Boston, Massachusetts, United States

and more 86 locations

Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])

Completed

Conditions: Multiple Myeloma

First Posted Date: 2016-04-18

Last Posted Date: 2022-06-21

Lead Sponsor: Celgene

Target Recruit Count: 578

Registration Number: NCT02741544

Locations: 🇯🇵
Shinko Hospital, Kobe, Hyogo, Japan

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

Phase 1

Completed

Conditions: Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell

Interventions: Drug: Durvalumab
Drug: Lenalidomide
Drug: Ibrutinib
Drug: Rituximab
Drug: Bendamustine

First Posted Date: 2016-04-11

Last Posted Date: 2023-11-18

Lead Sponsor: Celgene

Target Recruit Count: 106

Registration Number: NCT02733042

Locations: 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
Jefferson Medical Oncology Associates, Philadelphia, Pennsylvania, United States
🇫🇷
Centre Hospitalier Universitaire d'Avicennes, Bobigny Cedex, France

and more 62 locations

Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2016-02-26

Last Posted Date: 2022-06-30

Lead Sponsor: Celgene

Target Recruit Count: 22

Registration Number: NCT02692339

Locations: 🇵🇹
Hospital Professor Doutor Fernando Fonseca, E.P.E., Amadora, Portugal
🇵🇹
Hospital Central de Faro, Faro, Portugal
🇵🇹
Fundação Champalimaud, Lisboa, Portugal

and more 9 locations

Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease

Phase 2

Terminated

Conditions: Crohn's Disease

Interventions: Drug: GED-0301

First Posted Date: 2016-02-19

Last Posted Date: 2018-08-14

Lead Sponsor: Celgene

Target Recruit Count: 18

Registration Number: NCT02685683

Locations: 🇮🇹
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
🇮🇹
Policlinico Tor Vergata, Rome, Italy

A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Durvalumab
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2016-02-19

Last Posted Date: 2023-10-06

Lead Sponsor: Celgene

Target Recruit Count: 56

Registration Number: NCT02685826

Locations: 🇺🇸
Swedish Medical Center, Seattle, Washington, United States
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada

and more 51 locations

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Phase 1

Active, not recruiting

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: AG-120
Drug: Azacitidine
Drug: AG-221

First Posted Date: 2016-02-09

Last Posted Date: 2025-04-23

Lead Sponsor: Celgene

Target Recruit Count: 130

Registration Number: NCT02677922

Locations: 🇮🇹
Local Institution - 250, Pesaro, Italy
🇪🇸
Local Institution - 381, Madrid, Spain
🇪🇸
Local Institution - 380, Malaga, Spain

and more 46 locations

A Study to Assess Clinical an Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Route Clinical Practice Treating Pancreatic Cancer

Terminated

Conditions: Pancreatic Neoplasms

First Posted Date: 2016-02-02

Last Posted Date: 2019-09-16

Lead Sponsor: Celgene

Target Recruit Count: 44

Registration Number: NCT02670746

Locations: 🇳🇱
Gelderse Vallei, Ede, North Brabant, Netherlands
🇳🇱
LUMC, Leiden, South-Holland, Netherlands
🇳🇱
Spaarne Gasthuis, Haarlem, North Holland, Netherlands

and more 15 locations

Study of bb2121 in Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Biological: bb2121

First Posted Date: 2016-01-20

Last Posted Date: 2023-01-23

Lead Sponsor: Celgene

Target Recruit Count: 67

Registration Number: NCT02658929

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
National Cancer Institute, Bethesda, Maryland, United States
🇺🇸
Stanford Cancer Center, Stanford, California, United States

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy